Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8⁺ T cell immunity.

ABSTRACT: In simian-human immunodeficiency virus (SHIV)-infected non-human primates, broadly neutralizing antibodies (bNAbs) against the virus appear to stimulate T cell immunity. To determine whether this phenomenon also occurs in humans we measured HIV-1-specific cellular immunity longitudinally in individuals with HIV-1 starting antiviral therapy (ART) with or without adjunctive bNAb 3BNC117 treatment. Using the activation-induced marker (AIM) assay and interferon-γ release, we observe that frequencies of Pol- and Gag-specific CD8⁺ T cells, as well as Gag-induced interferon-γ responses, are significantly higher among individuals that received adjunctive 3BNC117 compared to ART-alone at 3 and 12 months after starting ART. The observed changes in cellular immunity were directly correlate

SUBMITTER: Rosas-Umbert M 

PROVIDER: S-EPMC9617872 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature